MEDVi states that its compounded programs carry the same price at every dose, so a provider-ordered dose change is not documented to raise the bill. What can change the bill is a switch of medication, route, or plan type. This guide separates those events, tabulates the verified policy for each MEDVi plan, and compares PlexusDx.

Many GLP-1 providers advertise an introductory rate, then raise prices by $50 to $120 monthly at refill. This analysis compares the first-month rate, the refill rate, and the true 12-month cost for compounded semaglutide and tirzepatide across twelve telehealth platforms.

A budgeting worksheet for MEDVi beyond the first month: the formula, the inputs verified on September 22, 2026, and worked totals for three, six, and twelve billing cycles for new patients and refill-only patients, with the same math applied to PlexusDx so the two can be compared on equal terms.

A line-item look at what a MEDVi bill contains: the compounded program price and what it bundles, the branded membership-plus-medication route, and which fees are included, separate, or not publicly verified. Worked totals for new patients are compared like for like with PlexusDx month-to-month plans.

MEDVi lists a daily compounded semaglutide tablet priced about $70 a month over its injection rate, with no tablet total published on its public page. This guide explains what is published for the oral plan, compares tablet to tablet and tablet to injection on the same terms, and sets out the questions to ask before choosing a route.

Whether MEDVi is worth its recurring price depends on how much of the bundled program you will use. This guide lists what MEDVi documents beyond the medication, separates included access from service promises, works the cost over three, six and twelve billing cycles, and shows where a leaner program such as PlexusDx may fit instead.